These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 17382266)

  • 21. Diagnostics of neuroendocrine tumours.
    Hodolic M; Fettich J; Banti E; Chondrogiannis S; Al-Nahhas A; Rubello D
    In Vivo; 2010; 24(5):771-4. PubMed ID: 20952747
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuroendocrine tumours: the role of imaging for diagnosis and therapy.
    van Essen M; Sundin A; Krenning EP; Kwekkeboom DJ
    Nat Rev Endocrinol; 2014 Feb; 10(2):102-14. PubMed ID: 24322649
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Carbidopa-assisted
    Helali M; Addeo P; Heimburger C; Detour J; Goichot B; Bachellier P; Namer IJ; Taïeb D; Imperiale A
    Ann Nucl Med; 2016 Nov; 30(9):659-668. PubMed ID: 27485404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NEN - the role of somatostatin receptor scintigraphy in clinical setting.
    Opalińska M; Hubalewska-Dydejczyk A; Sowa-Staszczak A; Stefańska A
    Nucl Med Rev Cent East Eur; 2016; 19(2):118-25. PubMed ID: 27479789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 18F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation.
    Imperiale A; Rust E; Gabriel S; Detour J; Goichot B; Duclos B; Kurtz JE; Bachellier P; Namer IJ; Taïeb D
    J Nucl Med; 2014 Mar; 55(3):367-72. PubMed ID: 24343986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The radionuclide molecular imaging and therapy of neuroendocrine tumors.
    Li S; Beheshti M
    Curr Cancer Drug Targets; 2005 Mar; 5(2):139-48. PubMed ID: 15810878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours.
    Sundin A
    Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):803-18. PubMed ID: 23582920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours.
    Ambrosini V; Tomassetti P; Rubello D; Campana D; Nanni C; Castellucci P; Farsad M; Montini G; Al-Nahhas A; Franchi R; Fanti S
    Nucl Med Commun; 2007 Jun; 28(6):473-7. PubMed ID: 17460538
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Other PET tracers for neuroendocrine tumors.
    Koopmans KP; Glaudemans AW
    PET Clin; 2014 Jan; 9(1):57-62. PubMed ID: 25029934
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of PET in localization of neuroendocrine and adrenocortical tumors.
    Eriksson B; Bergström M; Sundin A; Juhlin C; Orlefors H; Oberg K; Långström B
    Ann N Y Acad Sci; 2002 Sep; 970():159-69. PubMed ID: 12381551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional imaging of neuroendocrine tumors.
    Van Binnebeek S; Karges W; Mottaghy FM
    Methods Mol Biol; 2011; 727():105-22. PubMed ID: 21331931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach.
    Squires MH; Volkan Adsay N; Schuster DM; Russell MC; Cardona K; Delman KA; Winer JH; Altinel D; Sarmiento JM; El-Rayes B; Hawk N; Staley CA; Maithel SK; Kooby DA
    Ann Surg Oncol; 2015 Jul; 22(7):2295-301. PubMed ID: 25786743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Limited role of carbidopa-assisted
    Imperiale A; Averous G; Helali M; Taieb D; Pessaux P; Goichot B; Addeo P; Bachellier P
    Ann Nucl Med; 2019 Sep; 33(9):697-707. PubMed ID: 31214959
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Divergent role of (68)Ga-labeled somatostatin analogs in the workup of patients with NETs: AIIMS experience.
    Naswa N; Bal CS
    Recent Results Cancer Res; 2013; 194():321-51. PubMed ID: 22918767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management.
    Ito T; Jensen RT
    Curr Opin Endocrinol Diabetes Obes; 2017 Feb; 24(1):15-24. PubMed ID: 27875420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies.
    Eriksson B; Bergström M; Orlefors H; Sundin A; Oberg K; Långström B
    Q J Nucl Med; 2000 Mar; 44(1):68-76. PubMed ID: 10932603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current status of PET imaging of neuroendocrine tumours ([18F]FDOPA, [68Ga]tracers, [11C]/[18F]-HTP).
    Ambrosini V; Morigi JJ; Nanni C; Castellucci P; Fanti S
    Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):58-69. PubMed ID: 25677589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5-hydroxytryptophan positron emission tomography.
    Orlefors H; Sundin A; Lu L; Oberg K; Långström B; Eriksson B; Bergström M
    Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):60-5. PubMed ID: 16184369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imaging of Neuroendocrine Tumors.
    Öberg K; Sundin A
    Front Horm Res; 2016; 45():142-51. PubMed ID: 27002535
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Value of combined 6-[18F]fluorodihydroxyphenylalanine PET/CT for imaging of neuroendocrine tumours.
    Schiesser M; Veit-Haibach P; Muller MK; Weber M; Bauerfeind P; Hany T; Clavien PA
    Br J Surg; 2010 May; 97(5):691-7. PubMed ID: 20225244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.